ALNY vs BMRN
ALNY: Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases. BMRN: BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene therapies with a proven $3.2 billion commercial franchise.
Side-by-side fundamentals
| Metric | ALNY | BMRN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $266.99 | $58.40 | |
| Market cap as of 2026-07-23 | $36.2B | $11.3B | |
| P/E as of 2026-07-23 | 62.77 | 42.00 | BMRN lower |
| PEG as of 2026-07-23 | 1.11 | n/a | |
| Net margin as of 2026-07-23 | +13.5% | +8.3% | ALNY higher |
| Gross margin as of 2026-07-23 | +80.8% | +80.2% | ALNY higher |
| Operating margin as of 2026-07-23 | +16.6% | +9.7% | ALNY higher |
| ROE as of 2026-07-23 | +98.3% | +4.4% | ALNY higher |
| ROA as of 2026-07-23 | +11.8% | +3.4% | ALNY higher |
| Debt / equity as of 2026-07-23 | 2.52 | 0.23 | BMRN lower |
| Revenue growth (YoY) as of 2026-07-23 | +82.6% | +9.9% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +15.4% | ALNY higher |
| Beta as of 2026-07-23 | 0.24 | 0.23 | |
| 1-year return as of 2026-07-22 close | -15.3% | -1.4% | BMRN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.